San Francisco, Calif., October 9, 2012 – CollabRx, Inc. (NASDAQ: CLRX) today announces that Dr. Gavin Gordon, CollabRx Head of Business Development & Alliances, will participate as an invited speaker in the annual conference of the Oregon Bioscience Association to be held on October 9th and 10th at Marylhurst University.
The conference, titled “Bioscience Digitization and Discovery”, brings together industry authorities to discuss current topics impacting healthcare-related digital innovation. A key focus of the conference is how digital technology is producing widespread and significant changes in the healthcare industry. This shift is due to the emergence of wireless, mobile, and IT-related solutions being developed in response to the $300 billion value-added “big data” opportunity in the US health care market (as reported by McKinsey Global Institute). A large part of this market opportunity specifically targets areas in cancer and cancer genomics.
In his presentation, Dr. Gordon will discuss CollabRx’s cloud-based expert systems that inform healthcare decision-making by aggregating and contextualizing the world’s knowledge on molecular medicine with specific insights from the nation’s top clinical experts. These types of digital laboratory tools and techniques are critical in providing a clinically relevant framework to the massive quantities of tumor genetic data being produced (i.e., “big data”). Providing this interpretation at the point of care is increasingly becoming an important part of the clinical management of cancer patients.
At the conference Dr. Gordon will provide additional details on CollabRx’s recently announced partnership with Life Technologies to provide informatics-based solutions to physicians to aid in their interpretation of broad molecular panels and cancer diagnostics being developed by Life Technologies. Dr. Gordon will also give a live demonstration of the Therapy Finderä tool, a web-based expert system developed by CollabRx that serves as a common platform for both patients and physicians to encourage shared decision-making. A version of the Therapy Finderä is being made broadly available online via a recently announced partnership with MedPage Today, Everyday Health, Inc.’s physician portal that serves 96% of all oncologists and 1.6 million monthly online unique users.
Invited speakers also scheduled to attend the conference include Dr. Leroy Hood, President, Co-Founder, and Director at Institute for Systems Biology and other prominent thought leaders. Additional information on the conference can be found at the Oregon Bioscience Association website: www.oregonbio.org.
CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.
Safe Harbor Statement
This press release includes forward-looking statements about CollabRx’s anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx’s plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
James M. Karis, Co-CEO
Thomas R. Mika, Co-CEO
Robert Ferri Partners, LLC
(415) 575-1589 (direct)